PON1 and leukemia: Based on in vitro results, arterial occlusive events seem to be dose-related [20], and a post hoc analysis of data derived from three clinical trials on PON in Ph’+ leukemias suggested a 33% reduction in cardio- and cerebrovascular events for each 15 mg decrease in daily PON dose [21].